Pfizer Inc., is a global pharmaceutical company headquartered in New York City, New York, United States. It was founded by Charles Pfizer from Ludwigsburg. Pfizer is the second largest pharmaceutical company in the world after Roche, followed by Novartis.
According to Pfizer's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 7.65725. At the end of 2021 the company had a P/E ratio of 15.1.
Year | P/E ratio | Change |
---|---|---|
2021 | 15.1 | -29.02% |
2020 | 21.3 | 67.14% |
2019 | 12.7 | -41.9% |
2018 | 21.9 | 128.27% |
2017 | 9.60 | -63.56% |
2016 | 26.3 | -2.82% |
2015 | 27.1 | 32.06% |
2014 | 20.5 | 123.88% |
2013 | 9.17 | -24.1% |
2012 | 12.1 | -24.7% |
2011 | 16.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 21.1 | 175.72% | ๐บ๐ธ USA |
![]() Novartis NVS | 8.55 | 11.61% | ๐จ๐ญ Switzerland |
![]() Abbott Laboratories ABT | 22.9 | 199.03% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 49.3 | 544.27% | ๐บ๐ธ USA |
![]() Amgen AMGN | 18.6 | 142.60% | ๐บ๐ธ USA |
![]() Merck MRK | 17.5 | 128.57% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 21.6 | 182.42% | ๐บ๐ธ USA |
![]() AstraZeneca AZN | 102 | 1,225.54% | ๐ฌ๐ง UK |
![]() GlaxoSmithKline GSK | 4.22 | -44.85% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.